Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
I García-EscobarCancer and Thrombosis Section of the Spanish Society of Medical Oncology (SEOM)

Abstract

Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions.

References

Sep 12, 2006·Journal of Thrombosis and Haemostasis : JTH·A K Wittkowsky
Oct 11, 2007·Chest·Francisco José MuñozUNKNOWN RIETE Investigators
Oct 31, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology
Nov 21, 2007·Thrombosis Research·Alok A Khorana, Maithili V Rao
Jan 25, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Waldemar E WysokinskiRobert D McBane
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Sep 29, 2009·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Mallikarjun R ThatipelliWaldemar E Wysokinski
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Sep 11, 2010·Blood·Cihan AyIngrid Pabinger
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Jan 5, 2011·Mayo Clinic Proceedings·Alfonso J TafurJohn A Heit
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Dec 12, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY-EXT Investigators
Feb 22, 2013·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-SONATE Trial Investigators
Mar 15, 2013·Thrombosis Research·Anna FalangaCristina Verzeroli
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Sep 3, 2013·The New England Journal of Medicine·Harry R BüllerPhil Wells
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Dec 10, 2013·The Oncologist·Nicholas J Short, Jean M Connors
Dec 18, 2013·Circulation·Sam SchulmanUNKNOWN RE-COVER II Trial Investigators
Apr 16, 2015·Journal of Oncology Practice·Gary H LymanUNKNOWN American Society of Clinical Oncology
Jun 27, 2015·British Journal of Haematology·Henry G WatsonUNKNOWN British Committee for Standards in Haematology

❮ Previous
Next ❯

Software Mentioned

COVER
CASSINI
AVERT
AMPLIFY
RE
SELECT
AuriculA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Cirugía española
Juan I ArcelusGrupo de Trabajo de Trombosis de la Asociación Española de Cirujanos (Grupo TAEC)
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
Michael W Rich
© 2021 Meta ULC. All rights reserved